GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Genetic Technologies
Getaround is a car-sharing platform that allows people to rent out their personal cars. Its stock price is a story of the struggle for profitability in the highly competitive sharing economy.
Share prices of companies in the market segment - Medanalysis
Genetic Technologies is an Australian company that develops and markets genetic tests for predicting the risk of chronic diseases and cancer. We've categorized it as a "Medanalysis" company. The chart below shows how investors view the predictive medicine sector.
Broad Market Index - GURU.Markets
Genetic Technologies is an Australian company that develops and markets genetic tests for predicting the risk of chronic diseases and cancer. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with GENE's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
GENE - Daily change in the company's share price Genetic Technologies
Genetic Technologies Limited's daily price change reflects volatility in the genetic testing sector. The indicator demonstrates sensitivity to demand for its disease risk assessment tests, serving as an indicator of market conditions.
Daily change in the price of a set of shares in a market segment - Medanalysis
Genetic Technologies develops and markets genetic tests for assessing the risk of developing various diseases. The predictive medicine sector is innovative but also competitive. The chart below shows the volatility in this niche, allowing you to compare GENE's performance with other companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Genetic Technologies is an Australian company specializing in genetic testing for disease risk assessment. Its shares bring the dynamism of this cutting-edge medical field to the US market, adding an international dimension to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Genetic Technologies
Genetic Technologies Limited's year-over-year performance tells the story of its work in the predictive genetics market. Its market capitalization growth over the past 12 months reflects its success in commercializing its tests that assess the risk of cancer and other diseases. Its valuation reflects a bet that its approach will become part of standard preventative medicine.
Annual dynamics of market capitalization of the market segment - Medanalysis
Genetic, a biotech company, specializes in genetic testing. Its performance relative to the sector will determine how well its tests are accepted in the market and how it is impacted by changes in the reimbursement system, a key factor for companies in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Genetic Technologies, with its tests for disease risk assessment, reflects the progress in personalized medicine. Its ability to stay ahead of the market depends on how its tests become standard practice in healthcare. It's a long road from scientific development to mass adoption.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Genetic Technologies
Genetic Tech is a company specializing in genetic testing. Its monthly performance reflects progress in the commercialization of its disease risk detection tests. News about partnerships with clinics and increased testing volumes are key.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Genetic Technologies develops and markets genetic tests for assessing the risk of developing various diseases, including cancer. The dynamics of the medical diagnostics sector reflect the trend toward preventive and personalized medicine. Against this backdrop, the company strives to make its tests the standard for early risk detection and health management.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Genetic Technologies Limited is an Australian company specializing in the development and sale of genetic tests for predicting the risk of chronic diseases and cancer. The company's future depends on the acceptance of its tests. The broader market graph allows us to assess the extent to which its innovative predictive medicine products have gained market share, regardless of general sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Genetic Technologies
Genetic Technologies Limited is an Australian company specializing in genetic tests for disease risk prediction. Its weekly stock price is driven by the commercial success of its tests and partnerships with medical institutions.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Genetic Technologies develops genetic tests to predict the risk of various diseases. The company operates at the forefront of preventive medicine. The chart will show whether GEN's share price fluctuations are driven by its unique scientific developments and the commercialization of its tests or reflect general trends in genetic diagnostics.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Genetic Technologies is a medical diagnostics company. Its success depends on the adoption of its tests, not the economy. This chart shows how the company's shares have a life of their own, often ignoring overall market fluctuations.
Market capitalization of the company, segment and market as a whole
GENE - Market capitalization of the company Genetic Technologies
Genetic Technologies' market capitalization reflects its focus on developing tests to predict genetic risks for various diseases. Its volatile price action reflects investors' perceptions of its ability to commercialize these tests and demonstrate their clinical utility. It's a bet on the future of preventive medicine.
GENE - Share of the company's market capitalization Genetic Technologies within the market segment - Medanalysis
Genetic Technologies is a company specializing in genetic testing for disease risk prediction. Its market share in the medical diagnostics sector is small. Its market capitalization reflects the market valuation of its tests and its ability to compete in the rapidly developing and competitive field of predictive medicine.
Market capitalization of the market segment - Medanalysis
The chart below shows the total value of the genetic diagnostics sector. Genetic Technologies is an Australian company developing tests to assess the risk of hereditary diseases and cancer. The growth of this market reflects the revolution in personalized medicine. Genetic Technologies aims to become a leader in the field of predictive genetics.
Market capitalization of all companies included in a broad market index - GURU.Markets
Genetic Technologies is an Australian company that develops genetic tests to assess the risk of developing various diseases, including cancer. Its market capitalization is driven by predictive medicine. The chart below shows the economic weight of the genetic testing sector.
Book value capitalization of the company, segment and market as a whole
GENE - Book value capitalization of the company Genetic Technologies
Genetic Technologies' foundation is its laboratories and intellectual property in a portfolio of genetic tests for assessing the risks of various diseases, including cancer. The chart shows how this diagnostics company is investing in science and technology to build its core asset—a portfolio of tests capable of predicting health risks.
GENE - Share of the company's book capitalization Genetic Technologies within the market segment - Medanalysis
Genetic Technologies develops genetic tests for disease risk assessment. The chart shows its share of real assets. These are its certified laboratories, which provide the necessary resources for complex DNA analysis.
Market segment balance sheet capitalization - Medanalysis
Genetic Technologies is a company specializing in genetic testing for disease risk prediction. Their business requires certified laboratories. The book value chart shows the value of this scientific infrastructure, which forms the foundation of their diagnostic services.
Book value of all companies included in the broad market index - GURU.Markets
Genetic Technologies' resources are their certified laboratories in Australia, equipped with genetic testing equipment. The chart shows how the cost of this diagnostic infrastructure has changed.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Genetic Technologies
Genetic Technologies develops predictive genetic tests for disease risk assessment. Its value lies in its scientific research and patents. The chart below reflects investor confidence in the commercial potential of its tests. Market valuation trends will reveal the market's belief in the future of personalized medicine.
Market to book capitalization ratio in a market segment - Medanalysis
Genetic Technologies is a company specializing in the development and sale of genetic tests for predicting the risk of various diseases. Its value lies in its technology, algorithms, and scientific data. The chart shows how the market evaluates its scientific potential and commercial prospects in the field of predictive medicine.
Market to book capitalization ratio for the market as a whole
Genetic Technologies specializes in developing genetic tests for disease prediction. The company's value lies in its scientific research and patents. This chart shows that investors value the potential of its tests, not its lab equipment, creating a large gap between its market value and book value.
Debts of the company, segment and market as a whole
GENE - Company debts Genetic Technologies
Genetic Technologies is an Australian company specializing in the development of genetic tests for predicting the risk of various diseases. This chart shows how the company finances its commercial activities. Raising capital is necessary for clinical trials and global marketing of its tests.
Market segment debts - Medanalysis
Genetic Technologies specializes in developing genetic tests to predict the risk of various diseases. Preventive medicine is a promising area, but commercializing such tests is expensive. This chart shows how the company funds its research and development efforts.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Genetic Technologies
Genetic Technologies is an Australian company that provides genetic testing for disease risk assessment. This chart shows its financial structure. For a diagnostics company operating in an innovative field, it's important to have resources for research. Debt can limit these capabilities.
Market segment debt to market segment book capitalization - Medanalysis
Genetic Technologies is a company specializing in the development of genetic tests for predicting chronic disease risks. This chart shows the debt burden in the medical diagnostics sector. It helps understand how the company finances its research and commercialization of predictive tests in a competitive market.
Debt to book value of all companies in the market
Genetic Technologies specializes in genetic testing for disease risk prediction. This is a cutting-edge field of medicine that requires investment in research and laboratory capacity. This chart of total market debt helps us understand how the company finances its innovations and the sustainability of its financial model.
P/E of the company, segment and market as a whole
P/E - Genetic Technologies
Genetic Technologies is an Australian company specializing in the development and commercialization of genetic tests for assessing the risk of chronic diseases and cancer. This chart shows how investors view the future of predictive medicine.
P/E of the market segment - Medanalysis
Genetic Technologies is an Australian company specializing in predictive genetic diagnostics. It develops tests that assess the risk of developing chronic diseases such as cancer and diabetes based on genetics. This chart shows the average valuation for the medical analysis sector, reflecting how investors value the future of personalized and preventative medicine.
P/E of the market as a whole
Genetic Technologies is an Australian company specializing in genetic tests for predicting the risk of various diseases. Its valuation is a bet on the growth of the predictive medicine market. It is not tied to general economic cycles, but depends on the implementation of its tests in clinical practice and their acceptance by doctors and patients.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Genetic Technologies
Genetic Technologies is an Australian company developing genetic tests to predict the risk of developing chronic diseases such as cancer and diabetes. This chart reflects future revenue expectations, which depend on the commercialization and clinical adoption of its predictive tests.
%20P%2FE%20Genetic%20Technologies&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Genetic-Technologies&v=1772591925296 "Chart of the company's future (projected) P/E Genetic Technologies")
Future (projected) P/E of the market segment - Medanalysis
Genetic Technologies is a company specializing in predictive genetics, developing tests to assess the risk of chronic diseases and cancer. This chart shows general expectations for the healthcare sector. GENE's position relative to the average reflects investors' confidence in the clinical utility and commercial potential of its genetic tests.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772591925317 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Genetic Technologies is an Australian company specializing in the development and commercialization of genetic tests for assessing the risk of developing serious diseases such as cancer and diabetes. This chart of overall market expectations provides a backdrop for assessing the rapidly growing predictive medicine market, where genetics plays an increasingly important role.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772591925350 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Genetic Technologies
Genetic Technologies is an Australian company specializing in the development and commercialization of genetic tests for predicting the risk of developing various diseases, including cancer. Its financial performance, shown in the graph, depends on the number of tests sold and their successful implementation in clinical practice.
Profit of companies in the market segment - Medanalysis
Genetic Technologies is an Australian company specializing in the development and commercialization of genetic tests to predict the risk of developing common diseases such as cancer and diabetes. This chart shows the overall profitability of the medical testing sector. It illustrates the extent to which predictive genetics is becoming commercially viable and marketable.
Overall market profit
Genetic Technologies specializes in developing genetic tests to predict the risk of various diseases, including cancer. Demand for its products depends on the implementation of predictive medicine. Overall economic growth, reflected in this graph, allows healthcare systems and individuals to invest more in preventative measures, which facilitates the adoption of such tests.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Genetic Technologies
Genetic Technologies is an Australian company specializing in the development of genetic tests to predict the risk of serious diseases, such as cancer. This graph reflects analysts' expectations for the commercial success of its tests, which depends on their acceptance by the medical community and consumers.
%20profit%20of%20the%20company%20Genetic%20Technologies&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Genetic-Technologies&v=1772591925450 "Graph of future (projected) profit of the company Genetic Technologies")
Future (predicted) profit of companies in the market segment - Medanalysis
Genetic Technologies is a company specializing in the development of genetic tests to assess the risk of developing common diseases, such as cancer and cardiovascular disease. This chart shows forecasts for the medical diagnostics sector, helping to understand how predictive medicine from Genetic Technologies can transform approaches to prevention and healthcare.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772591925465 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Genetic Technologies specializes in developing genetic tests to predict disease risks. Demand for these services depends on market acceptance of the technology and healthcare budgets. The overall economic situation, reflected in the graph, can influence the willingness of individuals and healthcare systems to pay for preventive care.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772591925498 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Genetic Technologies
Genetic Technologies specializes in developing genetic tests to predict the risk of various diseases. This chart shows how investors value its predictive technology. The trend reflects confidence in the growth of the personalized and preventative medicine market and the commercial potential of its tests.
P/S market segment - Medanalysis
Genetic Technologies specializes in developing and selling genetic tests to assess the risk of developing various diseases, including cancer. Revenue comes from payments for these predictive tests. This chart for the medical diagnostics sector helps assess how investors view the scientific basis and commercial potential of Genetic Technologies' tests.
P/S of the market as a whole
Genetic Technologies is an Australian company specializing in the development of genetic tests to predict the risk of developing various diseases, including cancer and diabetes. This market revenue valuation chart helps understand how investors view the potential of the company's predictive medicine and technology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Genetic Technologies
Genetic Technologies is an Australian company specializing in the development and sale of genetic tests for predicting the risk of developing chronic diseases such as cancer and diabetes. This chart shows how investors estimate the future sales of its predictive tests. It reflects their expectations for growth in the personalized and preventive medicine market.
%20P%2FS%20Genetic%20Technologies&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Genetic-Technologies&v=1772591925560 "The graph of the company's future (projected) P/S Genetic Technologies")
Future (projected) P/S of the market segment - Medanalysis
Genetic Technologies is a company specializing in the development and commercialization of genetic tests for assessing the risk of developing various diseases, including cancer. The company's valuation reflects its attempt to establish itself in the field of predictive medicine, but also the challenges of widespread adoption and reimbursement for such tests.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772591925577 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Genetic Technologies develops and markets genetic tests for disease risk assessment. The company's growth is driven by advances in preventive and personalized medicine. This chart reflects general expectations, and GTG represents a knowledge-intensive sector shaping the future of healthcare.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772591925580 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Genetic Technologies
Genetic Technologies specializes in developing and selling genetic tests to assess disease risk. This chart shows revenue from sales of its tests, such as GeneType, which analyzes DNA to predict the risk of cancer, cardiovascular disease, and diabetes.
Sales of companies in the market segment - Medanalysis
Genetic Technologies (GENE) specializes in the development and sale of genetic tests for assessing the risk of developing chronic diseases such as cancer and diabetes. This figure reflects revenue in the healthcare analytics sector. The company's tests enable people to take proactive measures to maintain their health based on their genetic predisposition.
Overall market sales
Genetic Technologies specializes in developing genetic tests to predict the risk of various diseases. Demand for such predictive tests depends on the development of personalized medicine. This pattern of overall economic activity influences people's health spending. During periods of growth, people are more willing to spend money on preventative medical services not covered by insurance.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Genetic Technologies
Genetic Technologies is an Australian company specializing in the development and sale of genetic tests for predicting the risk of serious diseases, such as cancer and diabetes. Its revenue depends on the commercialization of these tests. This chart shows analyst revenue expectations, which is an indicator of the market adoption of predictive genetic diagnostics.
%20sales%20of%20the%20company%20Genetic%20Technologies&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Genetic-Technologies&v=1772591925641 "Schedule of future (projected) sales of the company Genetic Technologies")
Future (projected) sales of companies in the market segment - Medanalysis
Genetic Technologies specializes in developing genetic tests to predict the risk of various diseases, including cancer. This graph shows the potential future revenue from sales of their diagnostic tests. This is the analysts' perspective on the commercialization and implementation of predictive genetics in medical practice.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772591925644 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Genetic Technologies is an Australian company specializing in the development of genetic tests for predicting the risk of various diseases, including cancer. Its goal is to make preventative medicine more accessible. This graph shows general trends in healthcare, and the commercial success of the company's tests will be an indicator of society's readiness for genomic medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772591925657 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Genetic Technologies
Genetic Technologies is an Australian company specializing in the development of genetic tests for predicting the risk of various diseases, including cancer. Profitability depends on the commercial success of these tests and their acceptance by the medical community. The chart shows how the company aims to monetize its research in predictive medicine.
Market segment marginality - Medanalysis
Genetic Technologies is an Australian company specializing in the development and commercialization of genetic tests for assessing the risk of chronic diseases and cancer. This chart shows the profitability of its diagnostic business. Success depends on clinical validation, physician acceptance of the tests, and reimbursement from insurance companies.
Market marginality as a whole
Genetic Technologies is a company specializing in the development of genetic tests to predict the risk of various diseases. Demand for its services depends on the implementation of predictive medicine. This overall profitability chart reflects the financial health of healthcare systems, whose willingness to pay for such tests determines the company's commercial success.
Employees in the company, segment and market as a whole
Number of employees in the company Genetic Technologies
Genetic Technologies is a company specializing in predictive genetic testing. It develops tests that assess the risk of developing serious diseases such as cancer and diabetes. This graphic shows the team of scientists and specialists who transform genetic information into effective tools for preventative medicine.
Share of the company's employees Genetic Technologies within the market segment - Medanalysis
Genetic Technologies specializes in developing genetic tests to predict the risk of various diseases. Its business is based on scientific research and laboratory operations. This chart shows the company's team of scientists, geneticists, and technicians dedicated to transforming complex scientific data into practical tools for preventive medicine.
Number of employees in the market segment - Medanalysis
Genetic Technologies specializes in developing genetic tests to predict the risk of various diseases. This chart, which shows employment in the medical analytics sector, demonstrates the growing demand for personalized medicine. For Genetic Technologies, the growing number of geneticists and doctors using such tests means an expanding market for their products.
Number of employees in the market as a whole
Genetic Technologies specializes in the development and sale of genetic tests for predicting the risk of various diseases. Demand for predictive medicine is growing, but it depends on accessibility. The growth in overall employment, shown in this chart, supports the solvency of the population and the healthcare system, making advanced diagnostic tests more accessible to the general public.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Genetic Technologies (GENE)
Genetic Technologies (GENE) specializes in genetic testing and disease risk assessment. It is a diagnostic MedTech. This metric reflects the market value of its scientific foundation, test patents, and data analysis algorithms. Value is created in the laboratory and R&D, allowing for scalable testing with a relatively small staff.
%20of%20the%20company%20Genetic%20Technologies%20(GENE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Genetic-Technologies-GENE&v=1772591925880 "Chart of market capitalization per employee (in thousands of dollars) of the company Genetic Technologies (GENE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Genetic Technologies develops tests to assess the genetic risk of various diseases. In the field of predictive medicine, value is determined by the accuracy of the tests and intellectual property. This chart shows how the market values a company's scientific potential relative to its research team.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772591925904 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Genetic Technologies is an Australian company specializing in the development of genetic tests to predict the risk of various diseases. It is a player in the predictive medicine market. This chart for the company shows how its cost per employee in the genetic testing industry is determined by the value of its algorithms and scientific data.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772591925934 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Genetic Technologies (GENE)
Genetic Technologies is an Australian company specializing in genetic tests for predicting disease risks (such as cancer). It's a laboratory business. This chart shows the extent to which their laboratory is automated and the pricing power of their tests (brands) to generate profit per employee.
%20Chart%20Genetic%20Technologies%20(GENE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Genetic-Technologies-GENE&v=1772591925964 "Company Profit Per Employee (in thousands of dollars) Chart Genetic Technologies (GENE)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Genetic Technologies specializes in developing genetic tests to predict the risk of various diseases, including cancer. In the field of predictive medicine, value is created through scientific expertise and test accuracy. This metric demonstrates how a company monetizes its intellectual capital by turning scientific data into a commercial product.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772591925967 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Genetic Technologies (GENE) is a company specializing in the development and sale of genetic tests for assessing the risk of chronic diseases and cancer. This chart, showing average earnings per employee across all industries, helps investors assess the high-margin nature of the medical diagnostics sector, where precision and R&D are crucial, per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772591926000 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Genetic Technologies (GENE)
Genetic Technologies is an Australian company specializing in the development of genetic tests for predicting the risk of various diseases. Revenue per employee reflects the commercial success of its tests. The chart shows how successfully the company is selling its predictive tests to doctors and consumers, striving to make healthcare more personalized.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Genetic-Technologies-GENE&v=1772591926028 "Sales chart per company employee Genetic Technologies (GENE)")
Sales per employee in the market segment - Medanalysis
Genetic Technologies (GENE) is a company specializing in predictive genetics, developing tests to assess the risk of developing chronic diseases (cancer, diabetes). This chart shows the average revenue per employee in the segment. It helps evaluate how effectively GENE is commercializing its genetic tests compared to its competitors.
Sales per employee for the market as a whole
Genetic Technologies (GENE) is a company specializing in predictive genetics. They develop DNA-based risk assessments for chronic diseases such as cancer and diabetes. This metric demonstrates how effectively their lab and sales team are monetizing these innovative, yet niche, diagnostic tests.
Short shares by company, segment and market as a whole
Shares shorted by company Genetic Technologies (GENE)
Genetic Technologies (GENE) is an Australian company specializing in predictive genetic tests (disease risk assessment). This chart shows "short" interest. The high "bearish" bets reflect the speculative nature (micro-caps), doubts about the clinical utility and commercial success of such tests, and the intense competition in the genetic diagnostics sector. (348)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Genetic-Technologies-GENE&v=1772591926159 "Short Shares Chart for the Company Genetic Technologies (GENE)")
Shares shorted by market segment - Medanalysis
Genetic Technologies (GENE) specializes in developing genetic tests to predict the risk of serious diseases (cancer, diabetes). The chart below shows the overall short position in the genetic diagnostics sector. It reflects the level of investor skepticism about the commercialization of predictive tests.
Shares shorted by the overall market
Genetic Technologies is a small Australian company offering tests for genetic cancer risks. This chart illustrates the general fear. When investors are afraid, they sell off microcaps in biotech. They fear that in a recession, consumers will forgo expensive preventative tests not covered by insurance, which will hurt GENE's already meager revenue.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Genetic Technologies (GENE)
Genetic Technologies develops and markets tests for assessing genetic risk for various diseases, including cancer. This is predictive medicine. This indicator measures the "temperature" of the hype surrounding genomics. It "heats up" with news of new test launches and "cools down" in anticipation of actual sales data.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Genetic-Technologies-GENE&v=1772591926266 "RSI 14 indicator chart for the company's stock Genetic Technologies (GENE)")
RSI 14 Market Segment - Medanalysis
Genetic Technologies is an Australian company in the predictive medicine sector. It develops and markets tests (geneType) that assess genetic risk for chronic diseases, including cancer. This chart shows the overall sentiment in the medical diagnostics and genomics sector. It helps understand how investors view the industry and how GENE compares to its competitors.
RSI 14 for the overall market
Genetic Technologies (GENE), a cancer diagnostics company, is critically dependent on sentiment, as reflected in this chart. Market euphoria means open capital markets, making it easy to fund expensive clinical trials. In moments of market panic, investors flee unprofitable biotechs.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GENE (Genetic Technologies)
Genetic Technologies is an Australian company developing polygenic testing (PRS). They analyze DNA to predict a person's risk of developing chronic diseases (cancer, diabetes). This chart shows the speculative average price target from analysts, based on their belief in the commercialization and adoption of these predictive tests.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GENE-Genetic-Technologies&v=1772591926352 "A chart showing analyst consensus forecasts for the expected stock price. GENE (Genetic Technologies)")
The difference between the consensus estimate and the actual stock price GENE (Genetic Technologies)
Genetic Technologies is an Australian "predictive" diagnostics company. Their tests (geneType) analyze DNA to assess the *risk* of developing cancer or diabetes. This chart shows the difference between the market valuation and the consensus forecast. It indicates whether experts believe this "preventive" genetic testing will be commercialized.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GENE-Genetic-Technologies&v=1772591926400 "A chart showing the difference between the consensus forecast and the actual stock price. GENE (Genetic Technologies)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Genetic Technologies is an Australian diagnostic company developing tests (GeneType) to predict the risk of hereditary diseases (cancer, diabetes). This chart shows analysts' overall expectations for the entire medical testing sector. It reflects whether experts believe the predictive genomics market will grow.
Analysts' consensus forecast for the overall market share price
Genetic Technologies is an Australian company specializing in predictive medicine. They develop genetic tests (GeneType) for assessing the risk of cancer and other diseases. This chart shows overall market sentiment. For GENE, which operates in the "defensive" healthcare sector, overall optimism is important, but their growth depends more on the acceptance of their tests by insurance companies and doctors.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Genetic Technologies
Genetic Technologies (GENE) is an Australian diagnostic detective. Their specialty isn't treatment, but prediction: they use AI and genetic markers to assess the risk (polygenic risk score) of future diseases (cancer, diabetes). This chart is a pure indicator of their R&D. It reflects their (very slow) path to commercialization and their (speculative) bet on predictive medicine.
AKIMA Market Segment Index - Medanalysis
Genetic Technologies is an Australian company specializing in predictive health analytics. They use genetic testing to assess the risk of developing breast and prostate cancer long before it occurs. This chart compares their composite index to the sector, showing how their predictive DNA model outperforms the competition.
The AKIM Index for the overall market
Genetic Technologies is an Australian molecular diagnostics company offering tests for assessing the risk of cancer and other diseases (geneType). This chart, reflecting the market average, is a backdrop. It helps assess how GENE, which promotes preventive medicine, fits within the context of overall macroeconomic trends.
